1. Abdou Y, Pandey M, Sarma M, Shah S, Baron J, Ernstoff MS (2020) Mechanism-based treatment of cancer with immune checkpoint inhibitor therapies. Br J Clin Pharmacol 86:1690–1702
2. Akhurst RJ, Derynck R (2001) TGF-β signaling in cancer—a double-edged sword. Trends Cell Biol 11:S44–S51
3. Anderson AC, Joller N, Kuchroo VK (2016) Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity 44:989–1004
4. Andrews LP, Marciscano AE, Drake CG, Vignali DA (2017) LAG 3 (CD 223) as a cancer immunotherapy target. Immunol Rev 276:80–96
5. Ascierto PA, Melero I, Bhatia S, Bono P, Sanborn RE, Lipson EJ, Callahan MK, Gajewski T, Gomez-Roca CA, Hodi FS (2017) Initial efficacy of anti-lymphocyte activation gene-3 (anti–LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti–PD-1/PD-L1 therapy, vol 35. American Society of Clinical Oncology, p 9520